ES2195577T3 - Derivados de epotilon, procedimiento para su preparacion y su utilizacion. - Google Patents

Derivados de epotilon, procedimiento para su preparacion y su utilizacion.

Info

Publication number
ES2195577T3
ES2195577T3 ES99926300T ES99926300T ES2195577T3 ES 2195577 T3 ES2195577 T3 ES 2195577T3 ES 99926300 T ES99926300 T ES 99926300T ES 99926300 T ES99926300 T ES 99926300T ES 2195577 T3 ES2195577 T3 ES 2195577T3
Authority
ES
Spain
Prior art keywords
epotilon
derivatives
procedure
preparation
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99926300T
Other languages
English (en)
Spanish (es)
Inventor
Gerhard Hoefle
Thomas Leibold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Original Assignee
Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum fuer Infektionsforschung HZI GmbH filed Critical Helmholtz Zentrum fuer Infektionsforschung HZI GmbH
Application granted granted Critical
Publication of ES2195577T3 publication Critical patent/ES2195577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES99926300T 1998-05-08 1999-05-07 Derivados de epotilon, procedimiento para su preparacion y su utilizacion. Expired - Lifetime ES2195577T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19820599A DE19820599A1 (de) 1998-05-08 1998-05-08 Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung

Publications (1)

Publication Number Publication Date
ES2195577T3 true ES2195577T3 (es) 2003-12-01

Family

ID=7867085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99926300T Expired - Lifetime ES2195577T3 (es) 1998-05-08 1999-05-07 Derivados de epotilon, procedimiento para su preparacion y su utilizacion.

Country Status (14)

Country Link
US (2) US6982280B1 (https=)
EP (1) EP1077980B1 (https=)
JP (1) JP2002514649A (https=)
KR (1) KR20010052325A (https=)
AR (1) AR018344A1 (https=)
AT (1) ATE234842T1 (https=)
AU (1) AU754212B2 (https=)
CA (1) CA2330812A1 (https=)
DE (2) DE19820599A1 (https=)
ES (1) ES2195577T3 (https=)
HU (1) HUP0102283A3 (https=)
IL (1) IL139480A0 (https=)
TW (1) TW568910B (https=)
WO (1) WO1999058534A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
SI1483251T1 (sl) 2002-03-12 2010-03-31 Bristol Myers Squibb Co C cian epotilonski derivati
DE10355223A1 (de) * 2003-11-26 2005-06-30 Institut für Pflanzenbiochemie (IPB) Neue Makrocyclen zur Behandlung von Krebserkrankungen
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US20110104664A1 (en) 2006-03-31 2011-05-05 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5351146A (en) * 1993-03-01 1994-09-27 At&T Bell Laboratories All-optical network architecture
US5781537A (en) * 1995-07-07 1998-07-14 International Business Machines Corporation Setting up, taking down and maintaining connections in a communications network
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6304349B1 (en) * 1998-06-30 2001-10-16 Lucent Technologies Inc. WDM optical communications networks and methods for provisioning
US6445844B1 (en) * 1999-09-15 2002-09-03 Xros, Inc. Flexible, modular, compact fiber optic switch
US7092633B2 (en) * 2000-11-14 2006-08-15 University Of Texas System Board Of Regents System and method for configuring optical circuits
US6982951B2 (en) * 2000-12-21 2006-01-03 At&T Corp. Method for selecting a restoration path in a mesh network
US7212495B2 (en) * 2001-02-21 2007-05-01 Polytechnic University Signaling for reserving a communications path
AU2002305113A1 (en) * 2001-03-29 2002-10-15 Atoga Systems, Inc. Open ring architectures for optical wdm networks
US20020194339A1 (en) * 2001-05-16 2002-12-19 Lin Philip J. Method and apparatus for allocating working and protection bandwidth in a telecommunications mesh network
AU2002351589A1 (en) * 2001-06-27 2003-03-03 Brilliant Optical Networks Distributed information management schemes for dynamic allocation and de-allocation of bandwidth

Also Published As

Publication number Publication date
EP1077980B1 (de) 2003-03-19
EP1077980A2 (de) 2001-02-28
US20040259922A1 (en) 2004-12-23
KR20010052325A (ko) 2001-06-25
CA2330812A1 (en) 1999-11-18
AU754212B2 (en) 2002-11-07
ATE234842T1 (de) 2003-04-15
US6982280B1 (en) 2006-01-03
IL139480A0 (en) 2001-11-25
WO1999058534A3 (de) 2000-01-13
DE59904632D1 (de) 2003-04-24
HUP0102283A2 (hu) 2001-10-28
TW568910B (en) 2004-01-01
AR018344A1 (es) 2001-11-14
DE19820599A1 (de) 1999-11-11
WO1999058534A2 (de) 1999-11-18
JP2002514649A (ja) 2002-05-21
HUP0102283A3 (en) 2002-03-28
AU4361199A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
ES2195577T3 (es) Derivados de epotilon, procedimiento para su preparacion y su utilizacion.
ES2194446T3 (es) Derivados de bibiclooctano utilizados como plastificantes.
ES2196054T3 (es) Derivados de acido fenilacetico, procedimiento y productos intermedios para su obtencion y agentes que contienen los mismos.
BR9909961A (pt) Derivados de cadeia lateral alquila e alquenila funcionalizados de glicinamidas como inibidores de farnesil transferase
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
MX9302214A (es) Derivados de taxol y proceso para su preparacion
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
EP0513387A4 (en) Active oxygen inhibitor
BR0112370A (pt) Derivados de glutaramida substituìda com ciclopentila como inibidores de endopeptidase neutra
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ATE192649T1 (de) Stereochemische wortmanninderivate
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
IT1311922B1 (it) Composti farmaceutici.
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9204817A (es) Benzo(f)quinolinonas, procedimiento para su obtencion y formulacion farmaceutica que las contiene.
GT199900011A (es) Nuevos derivados del acido dihidroxihexanoico
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
BR0014461A (pt) Composto e método para preparar o mesmo
ES2001094A6 (es) Un procedimiento para la preparacion de un derivado de guanina
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
DK0671387T3 (da) Ny anvendelse af 1alfa-fluor-25-hydroxy-16-en-23-yn-cholecalciferol
ES2090238T3 (es) Derivados benzhidriloxietilpiperidilos de acidos alifaticos y su aplicacion en el tratamiento del asma y de sus alergias.
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
ES2164454T3 (es) Nuevos compuestos derivados de acido alquilendiamina di o tri-acetico, su procedimiento de preparacion, su utilizacion en composiciones cosmeticas y farmaceuticas y composiciones que los contienen.